| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 7, 2024 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 7, 2024 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/22/2023 | Buy → Hold | Laidlaw | |
| 1/20/2022 | $8.50 | Buy | Laidlaw & Co. |
| 1/11/2022 | $9.00 | Buy | Aegis Capital |
SC 13G/A - Cingulate Inc. (0001862150) (Subject)
SC 13D/A - Cingulate Inc. (0001862150) (Subject)
SC 13D/A - Cingulate Inc. (0001862150) (Subject)
KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to
CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming Medical Meeting CTx-1301 Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., March 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three and 12 months ended December 31, 2022, and provided a clin
Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include
KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate's lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercialization, and other therapeutic areas where the company's PTR™ technology may be applied. The Big Biz Show is nationally syndicated and can be seen and heard around the globe across a multitude of b
KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has commenced its final FDA-required study, which is a food effect study, for CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). A data readout from the study is expected by the end of 2024. Additionally, Cingulate has raised over $10 million in additional capital since the middle of August 2024, 58% of this amount from its at the market fa
4 - Cingulate Inc. (0001862150) (Issuer)
4 - Cingulate Inc. (0001862150) (Issuer)
https://register.epo.org/application?number=EP16756485
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 0.1% on Thursday. Following the market opening Thursday, the Dow traded up 0.06% to 39,745.57 while the NASDAQ rose 0.08% to 18,661.87. The S&P 500 also rose, gaining, 0.04% to 5,636.44. Check This Out: Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3 Leading and Lagging SectorsMaterials shares jumped by 1.2% on Thursday. In trading on Thursday, financials shares fell by 0.1%. Top Headline The Consumer Price Index in the United States slowed more than expected in June. Headline CPI inflation slowed from 3.3% in May 2024 to 3% in June 2024 on a year-over-year basis,
10-Q - Cingulate Inc. (0001862150) (Filer)
8-K - Cingulate Inc. (0001862150) (Filer)
8-K - Cingulate Inc. (0001862150) (Filer)
4 - Cingulate Inc. (0001862150) (Issuer)
4 - Cingulate Inc. (0001862150) (Issuer)
4 - Cingulate Inc. (0001862150) (Issuer)
Laidlaw downgraded Cingulate from Buy to Hold
Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50
Aegis Capital initiated coverage of Cingulate with a rating of Buy and set a new price target of $9.00
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i